{"id":203233,"name":"SANOFI U.S. SERVICES, INC.","slug":"sanofi-u-s-services-inc","state":"DC","description":"Multinational Pharmaceutical Company.","totalSpending":1360000,"filings":23,"yearlySpending":[{"year":2019,"income":100000},{"year":2020,"income":120000},{"year":2021,"income":180000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"firms":["MARSHALL & POPP, LLC"],"lobbyists":["MONICA POPP","HAZEN MARSHALL"],"issues":["HCR","MMM","PHA","TRD","TAX","BUD","CPT",null],"sampleDescriptions":["Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement.  Corporate tax issues.","Patents and protection of intellectual property issues, including S.1416: Affordable Prescriptions for Patients Act of 2019.","Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019.\n\nBiosimilars.\n\nImportation of prescription drugs.\n\n340B issues.\n\nFDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.","Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19: Lower Costs, More Cures Act of 2019.\n\nBiosimilars.\n\nImportation of prescription drugs.\n\n340B issues.\n\nFDA regulatory issues, including the International Pricing Index.","Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.\n\nIssues related to supply chain and Buy America requirements.\n\nBiosimilars.\n\nImportation of prescription drugs.\n\n340B issues.\n\nFDA regulatory issues, including the International Pricing Index.\n\nIssues related to the COVID-19 pandemic.","Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.\n\nIssues related to supply chain and Buy America requirements.\n\nBiosimilars.\n\nImportation of prescription drugs.\n\n340B issues.\n\nFDA regulatory issues, including the International Pricing Index.\n\nIssues related to the COVID-19 pandemic, including H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, and S.4775: Delivering Immediate Relief to America's Families, Schools and Small Businesses Act. H.R.133 [116th]: Consolidated Appropriations Act, 2021.","Issues related to protection of intellectual property.","Issues related to prescription drug value, supply chains, 340B, and the COVID-19 pandemic, including:\n\n*S.Con.Res. 5, fiscal year 2021 budget resolution.\n\n*H.R.1319: American Rescue Plan Act of 2021.","Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and S.1260, the United States Innovation and Competition Act.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.","Issues related to the False Claims Act, including amendments to H.R.3684 - Infrastructure Investment and Jobs Act.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res.14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and H.R.4521/S.1260, the United States Innovation and Competition Act.","Issues related to the False Claims Act, including S.2428 - False Claims Amendments Act of 2021.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Inflation Reduction Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act, H.R.4521/S.1260, the United States Innovation and Competition Act, and H.R. 4346, the CHIPS and Science Act.","Issues related to prescription drug value, including implementation of H.R.5376, the Inflation Reduction Act. Issues related to vaccine development, distribution and injury compensation. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R. 2617, Consolidated Appropriations Act."],"years":[2019,2020,2021,2022,2023,2024,2025]}